|
Abstract: |
Submitted: 12 February 2016; Revised: 26 May 2016; Accepted: 28 May 2016; Published online first: 10 June 2016
Canada and Japan are two additional regions that developed legal and regulatory frameworks for approval of highly similar versions of previously approved reference biological products (RBPs), called ‘biosimilars’ or ‘follow-on biologics’. Canada’s medicines regulatory counterpart, Health Canada, began regulating biosimilars as ‘subsequent entry biologics’ (SEBs) following a guidance issued in March 2010, utilizing a hybrid approach to how it regulates its generic drug products, known as ‘subsequent entry drugs’ (SEDs) [1]. Like the European Union (EU), Canada’s first SEB was Omnitrope® (somatropin), which was approved in April 2009 [2], prior to the SEB guidance. But Canada has only one other approved SEB contained in two separate SEB applications, infliximab (RBP: Janssen’s Remicade)®, both originally submitted by Celltrion [3]. Canada’s regulatory approach to biosimilars is most closely aligned with the EU but has taken a different approach with regard to extrapolation for infliximab than the EU and other countries where it is approved. Canada’s biosimilar patent litigation provisions are similar to how Canada addresses its SEDs, which is also undergoing some possible internal revision to bring its pharmaceutical patent litigation linkage to be more closely aligned to other country’s systems, such as the US. Japan’s system for follow-on biologicals, implemented by Japan’s medicines regulatory counterpart, Pharmaceuticals and Medical Devices Agency (PMDA), is similar to Canada in that it is a hybrid of some approaches similar to the EU such as quality attributes based on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines, along with some Japanese litigation and product requirements that tend to favour RBPs, such as unique proprietary and non-proprietary names. Japan also licensed Omnitrope® (somatropin) early on to Sandoz in June 2009 following its FOB framework in March 2009 [4], and now has seven FOBs referencing five products including somatropin.
While Health Canada may follow class-specific guidances developed by the European Medicines Agency (EMA) for biosimilar product reviews, Health Canada reviews SEB applications on a case-by-case determination in view of its Food and Drugs Act, regulation and guidance. Health Canada requires SEBs to demonstrate similarity comparing physiochemical properties, biological activity, immunochemical properties, specifications and stability. SEBs in theory rely on comparator data in addition to their own safety, quality and efficacy data, where a non-Canadian RBP may be used under certain conditions rather than a Canadian RBP. Once approved, an SEB monograph includes results of the comparison of the SEB to the RBP and indications for approved use, but Health Canada allows no claims for bioequivalence or clinical equivalence. While a sponsor may conduct clinical studies to support interchangeability, such decisions are a province issue. Health Canada does not support automatic substitution, because SEBs and RBPs may make manufacturing changes over time. Health Canada has a number of posted SEB guidances, the most recent one is ‘Information and submission requirements for subsequent entry biologics (SEBs)’, draft released in December 2015 [5].
Health Canada has distinguished itself by taking a different position on extrapolation of indications for biosimilar versions of infliximab compared to other regulatory authorities. Remicade® is indicated for adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis (PsO), as well as in paediatric patients with CD and UC. While there are some differences between Celltrion’s infliximab and Remicade when looking at certain sensitive in vitro assays, EMA and other regulatory authorities assigned more weight to other assays that they considered more clinically relevant and that demonstrated similarity. EMA also judged RA to be a sufficiently sensitive clinical model in which to detect potential differences. The US Food and Drug Administration (FDA) appears to be heading in that direction with the US submission for infliximab by Celltrion/Hospira as well, as supported in an Advisory Committee hearing that occurred on 9 February 2016 and was approved on 6 April 2016. Health Canada, on the other hand, allowed extrapolation for most indications but not CD or UC, due to those differences observed in some in vitro studies and potential differences in the mechanism of action of infliximab in the conditions, and the absence of clinical studies for those indications. Some debate continues in the medical community about whether the data in RA and AS would provide an adequate foundation for extrapolation to other indications.
Japan in contrast has in total nine biosimilars, referencing six products including one somatropin product, previously referenced [6]. Japan’s regulatory scheme requires follow-on biologicals to have highly similar quality (analytics using the active ingredient, preferably, or the drug product) that has no adverse impact on safety and efficacy to a previously licensed referenced product in Japan. Japan’s quality attributes are derived from comparability/equivalence studies, which are based on ICH guidances and observed differences in the products from non-clinical and clinical studies, including comparability in terms of safety and efficacy, where pharmacodynamic/pharmacokinetic studies may substitute for efficacy studies. In these situations, safety including immunogenicity studies are considered, especially for the formation of antibodies. Japan has issued guidelines for quality, safety and efficacy, and marketing approval including post-approval pharmacovigilance, [7] non-proprietary and drug names, [8] questions and answers, and product-specific safety communications [9]. Most of these publications are only available in Japanese with English translations as noted or summaries in various PMDA presentations [10].
Canada
Canada’s SEB patent litigation pathway is similar to its generic drug patent litigation pathway. Canada’s Minister of Health cannot grant a regulatory approval (called a ‘notice of compliance’ or ‘NOC’) to a generic/SEB filing (also known as a ‘piggy-back’ submission, which is based on a comparison to an innovator’s product), until the applicant addresses all patents listed by the innovator on a list of patents called the Patent Register. In some cases, a generic/SEB applicant will allege that a listed patent(s) is invalid or will not be infringed when it markets its proposed product, and the innovator may challenge those allegations in the Federal Court. Such submissions will then trigger the Regulations, if the party that filed the patents to the Patent Register files a prohibition order to granting the NOC within 45 days, resulting in litigation. During the litigation, the Minister may not grant an NOC to the generic/SEB applicant. At the end of the proceeding or 24 months, the Federal Court can prohibit the Minister from granting an NOC to the generic/SEB until relevant patent expiry, if it decides the generic/SEB allegations are not justified. Otherwise, the generic/SEB can obtain an NOC, subject to addressing the other patents, which may or may not block approval.
Canada’s provisions are brief but often lead to complex challenges in the context of this initial litigation phase. For instance, a generic/SEB applicant may challenge whether a patent is eligible for listing in the Patent Register or whether such listed patents need to be addressed by a particular generic/SEB applicant based on timing. In addition, a generic/SEB applicant may assert that an innovator is liable to pay damages to the generic/SEB applicant following an unsuccessful proceeding under the Regulations. Some recent and upcoming examples of NOC challenges for SEBs to watch include Amgen Canada et al. vs Apotex Inc (RBP Neupogen® (filgrastim)) (T-2072-12) (NOC hearing date 26 October 2015, dismissed 10 November 2015 and appealed), Sanofi-Aventis Canada Inc vs Eli Lily (RBP Lantus® [insulin glargine solution]) (T-2247-14) (NOC hearing date 24 May 2016), Amgen Canada vs Samsung Bioepis Co, Ltd (RBP Enbrel® (etanercept) (T-1283-15), and Janssen Inc. Celltrion Healthcare Co, Ltd and the Kennedy Trust (RBP Remicade® [infliximab]) (T-1478-15).
Regardless of the NOC outcome, the innovator can bring a patent infringement action or the subsequent entry applicant can bring an action to impeach the patent or make a counterclaim for invalidity when sued for infringement under section 60 of the Patent Act. The threshold for standing is relatively broad (‘any interested party’), but the would-be impeacher must pay security for legal costs into Court, i.e. an estimate of the patentee’s recoverable legal costs if they win. Such infringement/impeachment actions may proceed in as little as two years or sooner. This second wave of infringement litigations leads to the Canadian generic drug/biosimilar system being called a ‘double jeopardy’-type litigation system, i.e. there are two patent infringement litigation opportunities/risks.
At one point, it appeared that a patentee could not launch an infringement suit against a subsequent entry applicant without an NOC or product launch, because an application for an NOC subsequent entry approval was not an infringement nor were there sufficient grounds to maintain an infringement claim. Following Apotex vs Lundbeck (RLD: Cipralex® [escitalopram]), 2010 FC 807 (T-1407-09), however, it now appears that a patentee may be able to maintain a counterclaim of infringement in the absence of an NOC or product launch, if the subsequent entry applicant attempts to impeach based on non-infringement (but unclear if only invalidity).
The sequence of Apotex vs Lundbeck is somewhat unique and worth considering. Apotex filed an NOC, which was prohibited, and Apotex appealed. Prior to the appeal, Apotex filed an impeachment action against the patent including an argument for non-infringement. In response, the patentee filed a counterclaim for infringement. On motion to strike, the patentee admitted that there was no evidence that Apotex was infringing to date, and the action was based on Apotex’s desire to invalidate the patent and previous NOC application, which was not granted. The judge allowed the counterclaim to proceed, on the basis that while infringement might be somewhat speculative at that time, the interest of judicial economy suggested a strong benefit to have infringement of the future product considered at the same time as the impeachment.
This decision may be distinguished, however, because Apotex’s future product was easily defined and known to the parties based on the prior NOC submissions and non-infringement argument. Therefore, impeachment may not be an option filed concurrently with the NOC, if the generic applicant’s medicinal products are not finalized to a stage for a proper infringement analysis.
Based on some more recent cases, it appears that the decision in Apotex vs Lundbeck may lead to more patentee counterclaims in impeachment actions, which may increase their potential use, cost and complexity in SEB actions. For example, Hospira and Celltrion brought impeachments for Janssen’s Remicade® in March 2013. Celltrion obtained two NOCs for infliximab in January 2014, one for Inflectra® and one for Remsima®. But then in June 2014, Hospira took a cross-license to Inflectra®, and Janssen filed for judicial review, asserting that a patent listed after Celltrion originally filed must now be addressed for Hospira’s Inflectra®, because of the cross-license (but not for Celltrion’s Inflectra® or Remsima)®. Hospira’s NOC was then revoked with a trial date for 12 September 2016. The related patent case is Hospira Healthcare Corp vs The Kennedy Institute of Rheumatology (RBP Remicade® [infliximab]) (T-396-13).
Aside from NOC and impeachment, SEBs applicants may also consider filing certain pre-grant and post-grant patent proceedings in Canada. In a pre-grant proceeding, a third party may challenge a filed patent application using only published prior art documents accompanied by an explanation of why the art is pertinent under section 34.1 of the Patent Act or Protest pursuant to section 10 of the Patent Rules. In these proceedings, a challenger submits prior art plus a submission that questions patentability on a variety of grounds. In a post-grant proceeding, the petitioner moves for re-examination under section 48.1 of the Patent Act based on prior published art. Few SEB or biological applicants take advantage of these proceedings, however, because a third party is not permitted to communicate directly with the Examiner or Re-examination Board and is not even informed of any actions taken as a result of these interventions.
Japan
Much like Europe’s oppositions, Japanese biosimilar patent challengers prefer to utilize an invalidation procedure to patent litigation. Japan’s intellectual property resolution mechanism is a two-track system with the Board of Appeals of the Japan Patent Office (JPO) hearing trials for invalidation (post-grant patent proceedings), and the District Court hearing patent infringement actions [11]. Unlike the US and other jurisdictions, Japan has no prelaunch patent litigation process prior to generic drug or follow-on biological product launch. In addition, the PMDA will not approve generic drug or follow-on biological products before the substance or second medical use patents expire. As a result, the Japanese legal system experiences less generic drug or follow-on biological products patent litigation. This is the intent of the Japanese legal system because Japan wants to ensure a steady supply of pharmaceutical products and is concerned that patent litigation may remove generic drug or follow-on biological products from the market [12].
So in Japan, invalidation proceedings are generally the forum of choice to challenge patents. Invalidations are relatively fast, averaging approximately nine and half months, administered by the JPO Boards of Appeals panel, which consists of experienced appeal examiners. In an invalidation proceeding, a patent challenger may bring enablement and other obviousness analyses for complex technologies, including biotechnology products, and all grounds of invalidation may be considered. To avoid the invalidation, a patentee may demand that its patent claims are restricted or corrected. While a trial for invalidation is running, a judge may suspend or permit a district court patent infringement lawsuit to run concurrently. Anyone may bring an action for invalidation, but each party bears its own attorney fees.
As a second option, a patent challenger may also bring an infringement action in district court. All patent infringement hearings are heard before the Osaka or Tokyo District Court, which have exclusive jurisdiction over different geographic areas. Both of the district courts have designated intellectual property divisions, with technical advisors to brief judges on the complex technical matters in patent infringement cases. Patent infringement hearings are held at one- or two-month intervals until the deliberations are complete, not over consecutive days as in other countries. The parties to the proceedings submit briefs and evidence and expert opinions at each hearing, but parties rarely bring live examination of witnesses, and judges rarely grant motions for preliminary injunctions. If a party appeals an infringement action, its appeal primarily focuses on the briefs and includes little oral argument.
In a patent infringement action, the district courts may judge the invalidity of patents using a clear and convincing standard, where the JPO handles the invalidity portion and the district courts the ‘abuse of patents’ invalidity. In these proceedings, a patentee may demand necessary measures to prevent an act of infringement, including disposal of the alleged infringing products and removal of the facilities used for the alleged act of infringement. Because patent rights are a type of property right in Japan, infringement constitutes a tortious act, where damages are calculated under a special provision that includes the presumption of negligence and a reasonable amount of loss, and there is a special court fee calculation for damages. Only parties with standing may bring an action for patent infringement.
European Union update
Since the first part of this paper [13], one additional biosimilar product has been approved in Europe, the Samsung Bioepis version of Enbrel® (etanercept) called Benepali®, approved on 14 January 2016. According to Samsung Bioepis, Benepali® will be gradually rolled out across all 28 EU Member States as well as the European Economic Area (EEA) Member States of Norway, Iceland and Liechtenstein. In accordance with a commercialization agreement signed in 2013 between Samsung Bioepis and Biogen, Biogen will lead the commercialization and distribution of Benepali® in the EU and EEA Member States. There do not appear to be any ongoing patent oppositions or litigations associated with this product at this time.
United States update
In the US, the regulatory authority, FDA will keep the existence of a filed application confidential until the product is approved or the applicant discloses its application. When the first part of this paper [13] was submitted for publication, there were four publicly-disclosed filed biosimilar applications: Sandoz’s Zarxio® (filgrastim) (RBP Amgen’s Neupogen)®, Celltrion/Hospira Remsima® (infliximab) (RBP Janssen’s Remicade)®, Apotex’spegfilgrastim (RBP Amgen’s Neulasta)®, and Apotex’s Grastofil® (RBP Amgen’s Neupogen)®. In addition, Hospira had indicated that it had submitted an application for filing in December 2015, Retacrit® (epoetin alpha) (RBP Amgen’s Epogen® and Janssen’s Procrit)®, which Hospira later confirmed at or around March 2016 that FDA filed the application. In October 2015, however, Hospira announced that FDA issued a complete response letter and that Pfizer, which completed its acquisition of Hospira in the interim, intended to submit a complete response to FDA in the first half of 2016. Pfizer said that it did not believe that additional clinical studies appeared to be indicated. Also in October 2015, Sandoz announced that FDA had accepted for review its version of Amgen’s Enbrel® (etanercept). In November 2015, Amgen stated that FDA has accepted for filing its biosimilar version of Humira® (adalimumab). There do not appear to be current litigations surrounding the latest Sandoz and Amgen filings, but a patent information exchange is likely occurring given the more recent trend for applicants to share their 351(k) application and provide some manufacturing information.
Initial US litigations under the Biosimilars Patent Cooperation and Innovation Act (BPCI Act) largely have focused on procedural issues related to the ‘patent dance’. Initial US biosimilar actions were premature declaratory judgments by Sandoz for its biosimilar version of Enbrel® (etanercept) and Celltrion/Hospira’s version of Remicade® (infliximab). In both cases, the courts determined that the patent challenges were premature and did not have standing, because the biosimilar product applications at issue had not been filed with FDA yet. As a result, more recent would-be biosimilar applicants do not appear to have taken this early filing route.
An initial procedural ‘patent dance’ litigation that was filed after the biosimilar application was filed is Amgen vs Sandoz, which concerns the first FDA-approved biosimilar application, Sandoz’s version of Amgen’s Neupogen® (filgrastim), called Zarxio® (filgrastim-sndz, a ‘placeholder’ non-proprietary name, which FDA is still evaluating). Amgen initially filed its procedural challenge in a California District Court a lawsuit under California’s Unfair Competition Law and for conversion for failure to follow the default patent information exchange mechanism that would lead to pre-market patent litigation. In the same court, Amgen also moved for a preliminary injunction to prevent Sandoz’s market entry of Zarxio® pending a disposition on the merits. Here, Sandoz chose not to provide its biosimilar license application within 20 days of FDA’s notice of filing or other elements of the patent dance, yet ultimately provided Amgen with its biosimilars license application, resulting in the present lawsuit and a separate patent infringement suit for one patent, which has been stayed pending resolution of the procedural patent exchange suit. Sandoz disagreed with the Unfair Competition Law charge, arguing that the provisions of the default patent exchange and pre-market litigation are optional.
The California Court denied Amgen’s motion for a preliminary injunction and motion for a judgment on the pleadings. In conjunction with this action, Amgen filed a citizen petition with FDA to request that FDA not file any biosimilar application in its discretion, unless the applicant agreed to follow all procedures under the patent dance. FDA denied this petition on 25 March 2015, pending any contrary outcome in the litigation. Amgen then appealed the lower court’s decision.
The Federal Circuit heard oral arguments on the pleadings on 3 June 2015. The main issues in the case were whether a biosimilar applicant needs to engage in all steps of the patent dance to take advantage of the biosimilars approval pathway, or whether some or all of the steps are optional, and whether a biosimilar applicant can only provide 180-day notice of commercial launch after approval of the biosimilars license application or if notice of an intent to market following application approval is sufficient.
Sandoz prevailed in the Federal Circuit for the most part with a decision written by Judge Lourie dated 21 July 2015, but there were dissenting in-part opinions by Judges Newman and Chen. Lourie’s opinion affirmed dismissal of Amgen’s state law claims, including unfair competition and conversion. Sandoz’s counterclaims to permit it to launch its product prior to providing 180-day notice after FDA approval were vacated and remanded to the lower court to enter judgment consistent with the Court’s interpretation of the BPCI Act with an injunction pending appeal to Sandoz through 2 September 2015, corresponding to 180 days after its FDA product approval.
Lourie concluded that a 351(k) applicant can choose not to disclose its application as required (‘shall’ means ‘may’ in this context), leaving only remedies of the declaration of infringement, validity, or enforceability of any patent that claims the biological product or use of the biological product. Such infringement action further may include infringement of process patents, if the failure to disclose is coupled with an intent to obtain approval and market, use, or sell the biological product claimed in the patent or use of the biological product claimed in a patent before expiration of the patent. And both infringement actions would permit the RBP holder to access the 351(k) application through discovery, Lourie noted.
Lourie further concluded that a 351(k) applicant must (here ‘shall’ means ‘shall’) only give 180-day advance notice of commercial marketing after FDA has licensed the product. Lourie denied Amgen’s unfair competition claims (a California law-based claim), because the infringement claims are the only remedy. Lourie denied the conversion claims (also based on California law), because Amgen failed to establish the elements in particular that Sandoz could not reference Amgen’s BLA, because it failed to disclose its 351(k) application in a timely manner. Finally, Lourie denied Amgen’s preliminary injunction, because it was moot in view of the previous issues not being resolved.
Newman concurred and dissented in part. Newman said that she agreed that 180-day notice is mandatory and that it may only start with the approval of the 351(k). Newman disagreed, however, that the notice of acceptance of a 351(k) application is voluntary, arguing that it is a prerequisite to take advantage of the 351(k) approval pathway (‘shall’ means ‘shall’ in her opinion).
Chen dissented in part. He agreed that the 351(k) applicant’s failure to supply its application after filing was not a violation, because the RBP holder may still sue for infringement. Chen, however, disagreed that 180-day notice is mandatory or a ‘stand alone provision’, arguing that it was part of the voluntary patent exchange and fell when the 351(k) application was not shared as contemplated under the BPCI Act.
Both Amgen and Sandoz appealed and requested an en banc review, i.e. rehearing before the entire Federal Circuit, not a three-judge panel. Amgen agreed with Newman that 351(k) and manufacturing information must have been provided and the patent dance followed as a prerequisite for FDA to review and approve a 351(k) application. Amgen’s concurrent emergency injunction pending and its en banc review motions were denied, and Sandoz launched on 3 September 2015. Sandoz, meanwhile, requested a review of the 180-day notice requirement tied to 351(k) product approval. But both en banc appeals were denied, leaving open the question whether the issue would be appealed to the US Supreme Court. Amgen did not appeal, but Sandoz did on the last day of its extended time to file its petition for certiorari on 16 February 2016. The US Supreme Court can decide on its own whether to accept a case for review. With the unexpected death of Supreme Court Justice Antonin Scalia, if the Supreme Court decides to hear the case, there is the possibility for a split decision with the eight remaining justices. Scalia, in particular, had a strict interpretation of the legislation, which at times cast a swing vote for the justices. On 16 March 2016, US President Barack Obama nominated Judge Merrick Garland, Chief Judge for the US Court of Appeals for the District of Columbia Circuit, as Justice Scalia’s replacement. Given the proximity to Presidential elections, however, many believe that the Senate will not hold confirmation hearings until after the election.
A second ongoing biosimilar case under the BPCI Act is a continuation of the unsuccessful premature BPCI Act case brought by Celltrion/Hospira on behalf of its infliximab product. Here, Janssen proactively sued Celltrion/Hospira based on several patents in Janssen vs Celltrion and Hospira. In this case, Celltrion/Hospira timely provided Janssen their 351(k) application, but Janssen argued that certain required provisions of the BPCI Act were not followed, because Janssen asked for certain manufacturing information in connection with the 351(k) that was not provided. Celltrion/Hospira said sufficient manufacturing information was in the 351(k) already. Following the Amgen vs Sandoz Federal Circuit decision, Janssen moved for a preliminary injunction against Celltrion/Hospira to launch their biosimilar product until at least 180 days after FDA approval. Celltrion/Hospira have argued that the 180-day notice is not mandatory, if the 351(k) application is provided in a timely manner. The parties have stipulated to dismissal for the initial patents that were asserted in the case, so the main unresolved issue remains the product launch date after product approval.
At the District Court status conference in Janssen vs Celltrion, which followed the FDA Advisory Committee vote regarding the proposed approval of Celltrion/Hospira’s infliximab biosimilar on 9 February 2016, Celltrion’s counsel said that while Celltrion expected FDA approval in about four to eight weeks, Celltrion would not launch until after 29 June 2016, which is the expiration date of the patent covering the Crohn’s disease indication of infliximab. Janssen has brought a motion to stay the litigation pending its appeal of the United States Patent and Trademark Office’s (USPTO’s) Patent Trademark Appeal’s Board decision invalidating the patent covering the infliximab product (an inter partes review (IPR) action, discussed infra). Also pending is Janssen’s motion to amend the protective order to allow it to assert claims regarding an additional patent that was not in the original case. Janssen argued that Celltrion cannot launch until 2 October 2016, but in view of Celltrion’s imminent launch and the absence of an injunction, the judge has a scheduling conference set for 19 May 2016 to address these issues.
In third and fourth ongoing biosimilar application lawsuits, Amgen sued Apotex on its biosimilar version of Neulasta® (pegfilgrastim) and then its biosimilar version of Neupogen® (filgrastim). Amgen sued Apotex on 6 August 2015 for its pegfilgrastim product, following a 351(k) application exchange on 31 December 2014, with an initial hearing date of 11 July 2016, where the 180-day notice provision was in dispute as well as two patents. On 9 December 2015, Apotex lost its lower court challenge related to the 180-day notice provision, which it has appealed to the Federal Circuit, and has asserted counterclaims for patent misuse or sham patent litigation based on the two patents, which represented all of the unexpired patents in Amgen’s patent list. For one of the patents, Apotex told Amgen that it would not launch its product before the expiration of one of the other patents, and the second patent concerns a method of folding a protein that Apotex alleges is not relevant to any specific protein or its product. The Federal Circuit scheduled oral argument for this case on 4 April 2016. A similar lawsuit is unfolding for Apotex’s filgrastim product, following a 351(k) application exchange on 4 March 2015, also with two patents in suit, one of the same patents overlapping with its pegfilgrastim product. Both cases are in claim construction mode.
In addition to these types of legal proceedings, there are several options for biosimilar applicants to challenge patents that are more similar to what is commonly pursued in Europe and Japan – post-grant patent type reviews before the USPTO. An ex-parte re-examination is a type of post-grant review that may be brought at any time after patent grant. Anyone can bring an ex-parte re-examination challenge and such party may remain anonymous. In an ex-parte re-examination, a patent’s validity is challenged by establishing a substantial and new question of patentability, based on patents and printed publications, as well as claim scope statements made in court or before the USPTO. Ex-parte re-examinations are reviewed by the USPTO’s Central Reexamination Unit (CRU). After an ex-parte re-examination request is filed, a third party is generally precluded from further involvement, except it may file a response if the patent owner rebuts the request for review. A negative CRU decision may be appealed by the patent owner to the Patent Trial and Appeal Board (PTAB) or Federal Circuit. There is no legal estoppel, i.e. preclusion of bringing the same arguments in federal court, but a CRU decision may make it more difficult to invalidate the patent in federal court.
An initial type of post-grant review must be brought within nine months after patent issuance or a broadening reissue. A third party initiates the challenge with any legal challenge to validity for any claim under the standard that more likely than not the claim is not valid. The USPTO’s PTAB hears the challenge and such actions are typically completed within one year.
Following the nine-month post-grant review time period, an IPR proceeding may be brought. This type of post-grant review is most likely and was brought by Celltrion for an infliximab patent reference above that may be relevant to its infliximab biosimilar. As another example, more recently, Amgen brought an IPR for two patents related to Humira. Amgen’s IPR, however, was denied in January 2016. An IPR is also a third-party type review, but the review is limited to novelty or obviousness and may only be based on patents or printed publications under a preponderance of evidence standard. Like the post-grant review, the PTAB decides the challenge, and the decision may be appealed to the Federal Circuit. IPRs are generally completed within one year but have a maximum duration of 18 months.
A final type of patent litigation action that may be brought in the US is a Section 337 action before the United States International Trade Commission (ITC). These types of actions require litigants to allege as unlawful certain unfair practices in import trade, including infringement of intellectual property rights, and require a domestic industry in the US. The remedies for a Section 337 action are injunctive relief, i.e. product exclusion or a cease and desist finding, which does not include the possibility of damages. Section 337 actions permit broad discovery, but the findings have no preclusive court effect. These hearings are heard by administrative law judges (ALJs), and the decisions may be appealed to the Federal Circuit and may involve active participation by the Office of Unfair Import Investigations. The ALJ completes review within 10 to 12 months. A Commission Opinion and Remedial Order will then issue within 14 to 16 months, and there is the possibility for review by the President within 16 to 18 months.
There are many unresolved legal issues regarding biosimilars patent litigation in the four areas considered: Europe, US, Canada and Japan. As market update of biosimilars improves and FDA approves more biosimilars, will there be greater incentives for testing biosimilar patents in Europe before the US, especially if there is a unitary patent and a Unified Patent Court? Once FDA approves interchangeable biosimilars, how will this affect European patent challenges, especially for bridging products? For Europe to maintain its biosimilar lead, will revised avenues be provided to make patent challenges more attractive, perhaps in the Unified Patent Court?
In the US, the BPCI Act’s patent challenge mechanism is still not clear, in particular concerning whether the 180-day advance notice of marketing will continue to be found to occur only after FDA approves the 351(k) application. Because of this uncertainty and other potential procedural uncertainties, there may be unforeseen risks for a 351(k) applicant to launch ‘at risk’, i.e. before all of the potential patents at issue have been litigated to permit market entry. While certain post-grant patent challenges and the ITC look like potential venues in addition to federal courts for patent challenges, it is unclear how often these venues will be used for biosimilar patent challenges or how successful they will be. Finally, there are many unresolved regulatory issues, including FDA’s unresolved non-proprietary naming policy and interchangeability requirements, which may impact future biosimilar patent challenges.
In Japan, there appears to be a predisposition for innovator products rather than generic or biosimilar drug products. Will such predisposition continue to make biosimilar patent challenges in Japan less frequent? Over time, it is unclear how Japan will reconcile its policy goals to reduce cost and improve access to essential mediations with the general aversion for use of biosimilars over innovator products.
Finally, for Canada, how will the rebooted impeachment process affect prelaunch patent litigations, i.e. will there be more counterclaims? Will there be pressure to add finality to the proceedings under patent linkage to be more like other legal systems, especially in view of the Canada–Europe Comprehensive Economic and Trade Agreement (CETA), and how will this affect biological products?
|
Index of abbreviations/acronyms |
Special thanks to Mr Nathaniel Lipkus for his assistance with regard to Canadian pharmaceutical patent law, and Mr Ariel Weber for his translations and review of Japanese patent law and biosimilar regulatory review.
Disclosure of financial and competing interests: The author, or his law firm, represents companies that manufacture both reference biological and biosimilar biological products, including one or more of the companies referenced in the patent litigations contained in the paper. When discussing the cases referenced in this paper, the author has presented the arguments and opinions or orders in a factual manner without any commentary on the strength or weakness of any of the arguments thus presented.
Provenance and peer review: Commissioned; externally peer reviewed.
References
1. Health Canada. Notice: release of guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). 5 March 2010 [homepage on the Internet]. [cited 2016 May 26]. Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/notice-avis_seb-pbu_2010-eng.php
2. Sandoz Media Release. Sandoz Canada receives approval for recombinant human-growth hormone Omnitrope™, the first Subsequent Entry Biologic in Canada. 22 April 2009 [homepage on the Internet]. [cited 2016 May 26]. Available from: http://www.sandoz.ca/cs/groups/public/documents/document/n_prod_331056.pdf
3. Health Canada. Summary Basis of Decision (SBD) for Inflectra [homepage on the Internet]. [cited 2016 May 26]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php
4. Guideline for the quality, safety, and efficacy assurance of follow-on biologics. 4 March 2009 [homepage on the Internet]. Japanese. [cited 2016 May 26]. Available from: http://www.pmda.go.jp/files/000153851.pdf
5. Consultation on the revised guidance document: information and submission requirements for subsequent entry biologics (SEBs). 7 December 2015 [homepage on the Internet]. [cited 2016 May 26]. Available from: http://www.hc-sc.gc.ca/dhp-mps/consultation/biolog/consult-submission-seb-exigences-pbu-eng.php
6. GaBI Online – Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 May 26]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan
7. Marketing Approval Application for FOBs. 4 March 2009. (PFSB Notification 0304004).
8. Nonproprietary Name and Drug Name of FOBs. 14 February 2013. (PFSB/ELD Notification No. 0214-1, Administrative Notice).
9. Questions & Answers regarding Guideline. 21 July 2009; 31 March 2010; new supplement 15 December 2015. (PFSB/ELD Administrative Notice).
10. Daisaku Sato. Perspectives on trends in the regulation of biopharmaceutical products in Europe and Asia (Japan). Pharmaceuticals and Medical Devices Agency. 26 January 2016. Available from: https://www.pmda.go.jp/files/000209781.pdf
11. Kesan Jay P. A comparative appraisal of patent invalidation processes in Japan. IIP Bulletin 2004.
12. Okumura Y. IP Litigation in Life Sciences – Costs, Duration and Enforceability in Japan. World Intellectual Property Organization. WIPO Conference on IP Dispute Resolution in Life Sciences; 2015 May 22; Basel, Switzerland.
13. Malkin BJ. Biosimilars patent litigation in the EU and the US: a comparative strategic overview. Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(3):113-7. doi:10.5639/gabij.2015.0403.026
|
Author: Brian J Malkin, Esq, Senior Counsel, McGuireWoods LLP, Suite 400, 2001 K Street NW, Washington, DC 20006-1040, USA |
Disclosure of Conflict of Interest Statement is available upon request.
Copyright © 2016 Pro Pharma Communications International
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Source URL: https://gabi-journal.net/biosimilars-patent-litigation-in-canada-and-japan-a-comparative-strategic-overview-and-eu-and-us-update.html
|
Abstract: |
Submitted: 13 June 2015; Revised: 4 August 2015; Accepted: 6 August 2015; Published online first: 19 August 2015
The European Union (EU) was the one of the first highly regulated areas to develop a legal and regulatory framework for the approval for highly similar versions of innovator biological products, called ‘biosimilars’ or ‘follow-on biologicals’. While formal consideration of a biosimilar approval pathway began in the EU as early as 2001 [1], the European Commission first amended its market authorization provisions to include ‘similar biological medicinal products’ in 2003 [2], and issued its first general biosimilar guidance in 2005 [3]. The European Medicines Agency’s (EMA) first approval under the new similar biological medicinal product pathway was Sandoz’s somatropin called Omnitrope® in 2006 [4]. The EU currently has 19 biosimilars referencing five innovator biological products [4]. The US biosimilar pathway began in 2010 with the enactment of the Biosimilars Patent Cooperation and Innovation Act (BPCIA) [5] and has one approved biosimilar, Sandoz’s filgrastim-sndz [6] called Zarxio® in 2015 [7]. While the EU’s legal system is complicated by the lack of a unified patent litigation system that requires a multi-country patent litigation approach, the US’s biosimilar patent litigation has been complicated thus far by biosimilar applicants and the reference biological product (RBP) applicants picking and choosing what portion of the default patent litigation exchange system to utilize. Despite the differences between the prevalent litigation tactics in the EU and the US, as biosimilar approvals become more globalized, it will be increasingly important to appreciate these differences and consider how biosimilars patent litigation arguments and outcomes in one venue can benefit and be utilized in other venues, even if in different countries or legal systems.
The EU and the US have similar regulatory standards for biosimilars that would enable a manufacturer to make a biosimilar product that could in theory satisfy both regulatory standards, assuming that the RBP is the same. In the EU, a biosimilar must demonstrate similar quality and biological activity and demonstrate no meaningful differences in terms of safety or efficacy between the biosimilar and the RBP. EMA develops product-specific guidances through a consultative process that establishes common comprehensive comparability and immunogenicity studies required for biosimilar applicants to demonstrate biosimilarity for approval. As part of these requirements, biosimilar applicants are expected to conduct a product-by-product analysis using state-of-the-art bioanalytics and manufacturing along with clinical and regulatory experiences to support biosimilarity.
In the US, biosimilars must be highly similar to the RBP notwithstanding minor differences in clinically-inactive components. To demonstrate biosimilarity, there must be no clinically meaningful differences in terms of safety, purity, or potency—essentially safety and efficacy. So far, US Food and Drug Administration (FDA) has not developed product-specific guidances, preferring to issue more general guidances related to a product-specific development approach. Instead, each biosimilar product has its own approval requirements, developed in a stepwise approach, following multiple comparisons of the proposed biosimilar product to the RBP using state-of-the-art bioanalytics, where the required clinical studies and other study requirements are determined by how similar the products are as well as the observed bioanalytical differences.
Unique to the US, FDA may determine a biosimilar product is ‘interchangeable’ with the RBP. An interchangeable product may be substituted for the RBP without the intervention of the healthcare provider who prescribed the RBP. FDA may determine that a biosimilar product is interchangeable with the RBP if the biological product meets that highly biosimilar standard above plus: (1) the biosimilar product will produce the same clinical result as the RBP in any given patient; and (2) if administered more than once to an individual, the risk in terms of safety or diminished efficacy or alternating or switching between using the biosimilar and RBP is no greater than the risk of using the RBP without such alternation or switch. But FDA has said that while by law it could accept for filing and review an interchangeable biosimilar application, in practice it would not approve a biosimilar as interchangeable without some confirmatory market evidence. In this context, FDA suggested that perhaps five years of post-approval safety data would be sufficient for an applicant to submit a supplement to its previously approved biosimilar application, requesting a finding of interchangeability. So in the near future, most biosimilar litigation in the US will likely not involve an interchangeable biosimilar product.
European patent opposition
In Europe, the opposition process to a patent granted by the European Patent Office (EPO) is the most common approach for challenging the RBP’s patents. In part, this appears to be because it enables a biosimilar manufacturer to challenge a RBP’s key patents in a single forum rather than multiple nation state patent courts. For example, oppositions were filed for epoetin (RBP Epogen® [Amgen]), filgrastim (RBP Neupogen® [Amgen]), infliximab (RBP Remicade® [Johnson and Johnson/Janssen]), insulin glargine (RBP Lantus® [Sanofi]), and somatropin (RBP Gentropin® [Pfizer]). EPO has 38 contracting states and provides unified patent prosecution and opposition with the option for national patents by applicant choice after prosecution. Oppositions may be filed by any public member(s) except the proprietor within nine months after the patent is granted, which has public notice.
But an opposition has limited grounds to revoke a patent, including: (1) the subject matter is not patentable; (2) the invention was not disclosed clearly or completely enough for one skilled in the art to perform the invention; or (3) the subject matter extends beyond the content of the application filed. From an opposition, there are a number of possible outcomes: (1) the opposition is rejected and the patent is maintained as granted; (2) the patent is maintained in amended form with a new published specification; or (3) the patent is revoked. Initial opposition decisions may be appealed within two months, and countries may have conflicting rules whether they stay, i.e. halt further legal process, national patent infringement actions while an opposition and any associated appeal is pending. The median time for an appeal is close to three years, which is the same approximate median time for an opposition for patents concerning pharmaceutical/biotechnology products.
National patent litigation
Concurrently or following an opposition, biosimilars patent litigation may begin in member countries; however, litigation in each county requires detailed knowledge of that country’s national patent litigation procedures. A RBP manufacturer may choose to bring an infringement action or a biosimilar applicant may bring a declaratory judgement action for one or more patent(s) that may be at issue. Given the differences in patent litigation rules and biosimilars regulatory applications, there may be advantages to bring an initial biosimilars patent litigation in the anticipated primary biosimilar markets, the place of business or manufacture of the RBP or biosimilar, or based on a perceived jurisdictional favouritism for the action. For example, Amgen brought its filgrastim patent infringement litigation in Germany, which is the only EU country with separate courts for infringement and invalidity and is preferred for patent enforcement. Teva, on the other hand, brought its declaratory judgement action against Amgen’s patents for the same product in the UK, which has specialized patent courts and a high rate of patent invalidity judgements. Because each country has its own court system where patent holders may enforce their patents, there is the possibility for conflicting patent enforcement decisions in different countries, where RBP and biosimilar manufacturers may pursue national patent litigations in member countries simultaneously or successively.
In this context, biosimilar manufacturers have employed a variety of tactics, depending on a particular member country’s perceived market and the strength of the patents at issue. One option is to wait out key patents to expire in each member country, as Hospira suggested it would do for Remicade® (infliximab) [8]. Another is to launch at risk, which is often considered in The Netherlands and the UK given their higher rate of invalidity decisions and accelerated proceedings with no or lower punitive/treble damages, i.e. damages higher than calculated or treble (triple damages), which is punitive to make up for intentional infringement. In other situations, to avoid a preliminary injunction, i.e. an injunction entered by a court prior to a final determination of the merits of a legal case, to restrain a party from going ahead with a course of conduct or compelling a party to continue with a course of conduct until the case has been decided, issued by the judge ex parte, i.e. without hearing the other side, a biosimilar manufacturer may file a ‘protective letter’ to inform the court beforehand in detail of its non-infringement and invalidity arguments. Such letter may request the court to take account of its arguments and may also request to be heard to prevent the ex parte measure. But it is at the court’s discretion to what extent the court will take account of this protective letter. Biosimilar manufacturers are more likely to consider protective letters in countries where patent proceedings take longer or tend to favour the patent holder, e.g. Belgium and Germany.
Yet other measures seek to avoid disruptive patent litigation prior to product approval or before product launch. For example, Hospira sought to invalidate certain patents for trastuzumab (RBP Herceptin® [Genentech/Roche]) in the UK even before product approval. The primary patent for Heceptin® with a supplementary protection certificate (SPC, a type of extension of the term or expiration date of a patent based on a product approval) expired on 28 July 2014, and two additional dosage and composition patents had been held invalid in an opposition with appeals pending. Hospira challenged those two patents and won a lower court decision in April 2014 [9] and an appeal on February 2015 [10], finding both patents invalid, where it further obtained a declaration of non-infringement for certain trastuzumab formulations. In some instances, a biosimilar manufacturer may also begin its national merit invalidity or non-infringement proceedings early to help prevent preliminary injunctions.
Unitary patent/Unified Patent Court
One option that may be possible for biosimilars litigation in the EU in the future is patent litigation in a proposed Unified Patent Court (UPC). The concept is that a unitary patent (UP) will be a single patent with a unitary effect for all contracting states and a unified court system for all patent litigations. Many EU countries have joined the UP/UPC with notable exceptions being Croatia, Poland and Spain. The European Parliament and European Council approved the EU UP package in December 2012, with participating Member States signing the Agreement for a UPC in February 2013. The UPC needs to be ratified by at least 13 signatory states to come into force including France, Germany, and the UK, and has so far been ratified by Austria, Belgium, Denmark, France, Luxembourg, Malta and Sweden. A potential fly in the ointment was an action brought by Spain before the EU Court of Justice, challenging the UP and applicable translation arrangements, which was dismissed on 5 May 2015 [11]. While the UPC is waiting for a final ratification by sufficient Member States, the infrastructure for a UPC is building within the EU.
A UPC has the advantages of one application leading to one patent, with one patent litigation action leading to one decision for all participating 25 states in a streamlined procedure. The streamlined litigation procedure has a series of steps: (1) Written Procedure (two writs per party normally on infringement and two on validity, if included); (2) Interim Procedure (includes all steps to comprehensively prepare the case for an oral hearing including conferences); (3) Preparation for Oral Hearing (all steps to prepare an oral hearing for the panel); (4) Oral Hearing (managed by three judges – two multinational and one non-state national – including witnesses, evidence, pleadings and cross-examination); (5) Decision on the Merits (includes decisions on injunctions, damages, accounting, validity and costs of proceedings); and (6) Appeals (based on points of law and matters of fact brought within two months of decision of the Court of First Instance or within 15 days of an order, where rehearings appear to be exceptional).
At this point, there is no UPC, but when ratified and effective, there will likely be a parallel system structure, i.e. a UPC and a national patent system, which has led to the question whether these will lead to an inadmissible double patent protection. While the new UPC system at this point has no case law, there is already contradictory case law in the participating Member States, leading to some initial uncertainty on how the UPC system will work. Some initial thoughts are that RBP holders will use the UPC system to protect their intellectual property in all participating states and continue to protect EPO and national patents in key markets either for a first litigation or as part of a fall-back plan.
Patent dance
The US biosimilar pathway includes new patent litigation provisions (aka ‘the patent dance’) that provide for a default exchange of information leading to at least two distinct phases of patent litigation with possible ramifications for failure to follow this default exchange. The proposed exchange mechanism differs in many ways from Hatch-Waxman patent litigation for small molecule drugs including: (1) there is no book like the ‘Orange Book’ that lists patents including claims to the active ingredient, product, or approved use(s) of the product [12]; (2) there are no patent certifications to FDA indicating potential patent challenges or a 30-month stay options for patent challenges by the RBP holder; (3) it relies on a voluntary exchange of information including the biosimilars application and information that describes the process(es) used to manufacture the biological product in the application and relevant patents as determined by the RBP holder and biosimilar applicant; (4) there are ramifications for not participating in the voluntary exchanges including limited litigation rights; (5) there are relatively short timeframes for the patent exchanges that, when followed, would yield a lengthy cycle before any infringement action after FDA accepts the biosimilar application for filing; (6) it envisions multiple patent litigation cycles following the initial exchange of patent lists, 180 days prior to commercial product launch, and post launch.
When everything is followed as provided in the default pre-approval patent litigation process, the following steps are indicated:
Notifications
– Within 20 days of FDA notification of the biosimilar’s application acceptance, the applicant sends notice of filing and a copy of its application to the RBP holder and such other information that describes the process or processes used to manufacture the biological product that is the subject of such application and may provide to the RBP holder additional information requested by or on behalf of the RBP holder (under statutory or otherwise-agreed-to confidentiality terms).
– Within 60 days, the RBP holder provides biosimilar applicant with a list of all patents for which it could bring a claim of patent infringement and a list of patents it is willing to license to the applicant.
– Within 60 days, the biosimilar applicant provides: (1) its own list of patents that it believes the RBP holder could bring a claim of patent infringement; (2) detailed statements (like in Hatch-Waxman Act) why, claim-by-claim, each patent is invalid, unenforceable, or not infringed by the applicant; (3) may include a statement when the applicant intends to launch, e.g. after expiration of one or more patents; and (4) whether it would consider a license to one or more patents listed by the RBP holder.
– Within 60 days, the RBP holder provides: its own detailed statements why, claim-by-claim, it believes each listed patent is valid, enforceable and infringed by the biosimilar applicant.
Litigation suits
– For 15 days of good-faith negotiations, the biosimilar applicant and RBP holder attempt to agree on a list of patents to litigate prior to product launch as an ‘artificial’ act of infringement, i.e. ‘artificial’ because there is no infringement until a product is marketed, but the litigation proceeds based on the biosimilar applicant’s assertion that it intends to market its biosimilar product, if approved, prior to expiration of one or more patents.
– If they fail to agree, the biosimilar applicant and RBP holder each compile their own list, with the biosimilar applicant responding first, and the RBP holder must reply within five days of provision of the biosimilar applicant’s list.
– The RBP holder’s list may not exceed the number of patents in the biosimilar applicant’s list, and if the biosimilar applicant’s list contains no patents, then the RBP holder may include one patent in the patent litigation list.
– Within 30 days, the RBP holder must bring suit against the biosimilar applicant with respect to the patents included in the lists (a ‘timely infringement suit’ and phase one).
– The RBP holder may only recoup a royalty if:
○ The RBP holder fails to bring a timely infringement suit; or
○ Following a timely infringement suit, the action is dismissed without prejudice or not prosecuted to judgement in good faith.
– Newly issued or licensed patents must be added to the patent lists within 30 days of issuance or licensing.
– The biosimilar applicant must provide 180 days advance notice prior to commercial launch, upon which (as to the patents to the lists as modified by newly issued or licensed patents):
○ The RBP holder or biosimilar applicant can seek a declaratory judgement; and
○ The RBP holder can sue for a preliminary injunction before the date of first marketing (phase two).
Like generic drug patent litigation following the Hatch-Waxman Act, which established a generic drug approval process in the US, US biosimilars patent litigation has been off to a bumpy start. The initial US biosimilars patent litigation actions were filed before the related biosimilars applications were filed, e.g. Sandoz’s version of Enbrel® (etanercept) and Celltrion/Hospira’s version of Remicade® (infliximab). However, both of these actions were denied by the courts because they were premature, so a similar strategy is unlikely to be followed by subsequent biosimilar applicants.
Two other biosimilar patent litigation actions appear to have included some but not all elements of the patent dance [13]. Reasons to avoid the patent dance include: (1) the maximum allotted times for each party in the patent dance may mean 250 days before a lawsuit after FDA has accepted the biosimilar application for filing, but FDA has a 10-month review cycle (~300 days), which could lead to an FDA approval prior to any substantive patent ruling; (2) the proposed confidentiality provisions and need for patent certainty before launch may not be viewed as insufficient for the biosimilar applicant to provide the RBP holder its proprietary application; (3) FDA’s review process appears to be separate from the patent dance; (4) the default patent information and list exchange leading to pre-launch patent litigation is expensive and unproven; (5) following market approval, there still exists the risk of another lawsuit for the marketed product; and (6) the EU model suggests alternative patent challenges via the Inter Partes Review (IPR) mechanism (a post-grant patent challenge at the United States Patent and Trademark Office (USPTO) versus the federal court system) and possibly the International Trade Commission (another type of patent challenge that may provide for an injunction for imported, infringing goods) or wait for relevant patents to expire, i.e. 12-year exclusivity means core patents may have limited life left.
One of the two actions is moving forward on the first FDA-approved biosimilar application, Sandoz’s version of Amgen’s Neupogen® (filgrastim), called Zarxio® (filgrastim-sndz). Amgen filed in a California District Court a lawsuit under California’s Unfair Competition Law and for conversion for failure to follow the default patent information exchange mechanism that would lead to pre-market patent litigation. In the same court, Amgen also moved for a preliminary injunction to prevent Sandoz’s market entry of Zarxio® pending a disposition on the merits. Here, Sandoz failed to provide its biosimilar license application within 20 days of FDA’s notice of filing or other elements of the patent dance, yet ultimately provided Amgen with its biosimilars license application, resulting in the present lawsuit and a separate patent infringement suit for one patent, which has been stayed pending resolution of the procedural patent exchange suit. Sandoz disagreed with the Unfair Competition Law charge, arguing that the provisions of the default patent exchange and pre-market litigation are optional. The California Court denied Amgen’s motion for a preliminary injunction and motion for a judgement on the pleadings. In conjunction with this action, Amgen filed a citizen petition with FDA to request that FDA not file any biosimilar application in its discretion, unless the applicant agreed to follow all procedures under the patent dance. FDA denied this petition on 25 March 2015, pending any contrary outcome in the litigation [14]. Amgen has appealed the lower court’s decision, and the matter is pending in the Federal Circuit, which heard oral arguments on the pleadings on 3 June 2015. The main issues in the case are whether a biosimilar applicant needs to engage in all steps of the patent dance to take advantage of the biosimilars approval pathway, or whether some or all of the steps are optional, and whether a biosimilar applicant can only provide 180-day notice of commercial launch after approval of the biosimilars license application or if notice of an intent to market following application approval is sufficient.
While Celltrion/Hospira failed to meet the standard for a declaratory judgement for several Janssen patents related to Remicade® (infliximab) prior to filing its application, it appears that Janssen has filed a patent litigation suit along with allegations that Celltion/Hospira failed to follow mandatory patent dispute procedures under the BPCIA, demanding that such procedures be followed. In this instance, Janssen has asserted that while Celltrion/Hospira timely provided its biosimilar license application to Janssen and followed some patent dispute procedures, Celltrion/Hospira failed to disclose required manufacturing process information requested by Janssen to develop its list of potential patents to litigate. Janssen has also asserted that Celltrion/Hospira failed to follow procedures under the BPCIA by illegally shortening the patent litigation negotiation process from the list of patents exchanged by Janssen and that Celltion/Hospira failed to provide an effective 180-day notice of commercial launch, because such notice may only be provided after application approval, which has not yet occurred. The issues are therefore similar as with the Amgen v. Sandoz case, namely whether all or some patent dance steps need to be followed according to the BPCIA and what constitutes notice of 180-day advance notice of commercial launch. No dispositive motions have been decided in this case related to these pending issues. And at this point, it is uncertain what information has been exchanged for the two other publicly noticed and pending biosimilar license applications filed by Apotex referencing Amgen’s Neupogen® (filgrastim) and Neulasta® (pegfilgrastim).
At this point, there appears to be limited patent litigation challenges in the EU with a preference to patent issuance challenges and some limited country patent challenges. There are many unresolved issues. As more biosimilar product applications are filed in the US, will there be greater incentives for testing patents in certain country markets before the US, especially if there is a UP/UPC, or will all major patent litigation continue to be in the US? Once FDA approves interchangeable biosimilars, how will that affect European patent challenges, especially for bridging products, i.e. similar or same biological products marketed in both the EU and the US? Will the Federal Circuit require biosimilar applicants to follow all steps of the patent dance, some of them, or none of them, at the discretion of the parties? Depending on the Federal Circuit’s decision in the Amgen v. Sandoz case, will Congress amend the US biosimilars approval or litigation pathway? Will other tactics that challenge patents outside the US Federal courts such as IPRs in the USPTO or litigation in the International Trade Commission become more frequent strategies similar to how oppositions are used in the EU, because biosimilar patent litigation is too unwieldy? We are just at the tip of the iceberg when it comes to biosimilar patent challenges.
The subsequent manuscript will look at patent challenges in Canada and Japan, along with updates for the EU and the US.
Index of abbreviations/acronymsIPR – Inter Partes Review |
Patent litigation for this manuscript is used broadly to mean to bring or defend a legal patent action, which may be in a court or before another judicial body, e.g. a patent review board, such as the European Patent Office or the United States Patent and Trademark Office, or another official governmental or quasi-judicial body, where a patent may be enforced or a patent challenged in terms of validity, infringement, or enforceability.
Disclosure of financial and competing interests: The author is an employee of McGuireWoods LLP. The author has no competing interests to disclose for this manuscript. The author wishes to note that he is a licensed patent attorney and also practices food and drug law in the US, not the European Union (EU). As a result, his comments regarding the legal system in the EU are based on his research and not his licensure to practice law in the EU. As noted in the manuscript, litigation in each jurisdiction requires detailed knowledge of that jurisdiction’s litigation procedures and should be in consultation with appropriate counsel.
Provenance and peer review: Commissioned; externally peer reviewed.
References
1.European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 17 December 2003. EMEA/CPMP/3097/02/Final [homepage on the Internet]. 2003 Dec 22 [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003963.pdf
2.Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. J Eur Union. 2003;L159:46-94.
3.European Medicines Agency. Guideline of similar biological medicinal products. 30 October 2005. EMEA/CHMP/437/04 [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://www3.bio.org/healthcare/followonbkg/GuidelineonSimilarBiologicalProducts.pdf
4.European Medicines Agency. EMA list of approved biosimilars [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001
d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType
=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit.
5.Patient Protection and Affordable Care Act, Pub.L. No. 111-148, 124 Stat. 119, tit. VII, subtit. A (2010).
6.FDA called this a ‚placeholder nonproprietary name,‛ because FDA is still deciding its nonproprietary naming procedures.
7.U.S. Food and Drug Administration. FDA approves first biosimilar product Zarxio [homepage on the Internet]. 2015 [cited 2015 Aug 4]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm
8.PR Newswire. Hospira launches first biosimilar monoclonal antibody (mAb) Infectra™ (infliximab) in major European markets [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=175550&p=irol-newsArticle&ID=2016883
9.British and Irish Legal Information Institute. Hospira UK Limited v. Genentech Inc. [2014] EWHC 1094 (Pat) (10 Apr 2014) [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://www.bailii.org/ew/cases/EWHC/Patents/2014/1094.html
10.Hospira (UK) Limited v. Genentech, Inc., [2015] EWCA Civ. 57. 6th February 2015 [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=175550&p=irol-newsArticle&ID=2016883
11.Court of Justice of the European Union. The Court dismisses both of Spain’s actions against the regulations implementing enhanced cooperation in the area of creation of unitary patent protection. Press release no 49/15. 5 May 2015 [homepage on the Internet]. 2015 May 5 [cited 2015 Aug 4]. Available from: http://curia.europa.eu/jcms/upload/docs/application/pdf/2015-05/cp150049en.pdf
12.FDA publishes a ‚Purple Book‛ that includes biologics license applications (BLAs) with interchangeability ratings for biosimilars, approval dates, and product names.
13.Because these litigations are pending and some related court papers have been filed under seal, there is a limited record to ascertain which elements were actually followed. Based on the public filings, it appears that the information exchange was somewhat other than that proposed in the statute, and this article reflects the author’s review of public information available from the associated court dockets as of July 1, 2015.
14.Requests FDA adopt policies and practices in their acceptance and review of biosimilar applications that will provide for the orderly implementation and efficient functioning of the Biologics Price Competition and Innovation Act (BPCIA). FDA Docket No. FDA-2014-P-1771 [homepage on the Internet]. [cited 2015 Aug 4]. Available from: http://www.regulations.gov/#!docketDetail;D=FDA-2014-P-1771
|
Author: Brian J Malkin, Esq, Senior Counsel, McGuireWoods LLP, Suite 400, 2001 K Street NW, Washington, DC 20006-1040, USA |
Disclosure of Conflict of Interest Statement is available upon request.
Copyright © 2015 Pro Pharma Communications International
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Source URL: https://gabi-journal.net/biosimilars-patent-litigation-in-the-eu-and-the-us-a-comparative-strategic-overview.html
Copyright ©2024 GaBI Journal unless otherwise noted.